Entries by admin

4P-Pharma at BIO-EUROPE 2021

4P-Pharma is attending BIO-Europe! Join us at the digital event, October 25–28, 2021. Revital Rattenbach, our chairwoman, and Roselina Lam, our business development and licensing-in manager, participate to the event. To learn more about us and discuss future partnership, please feel free to connect with us via the partnering platform For further information, click here

4Moving Biotech website is online!

It is our great pleasure to announce that 4Moving Biotech website is online! ​ 4Moving Biotech is a French biotech start-up company, subsidiary of 4P-Pharma, dedicated to the clinical development of 4P004, a first-in-class disease-modifying drug for osteoarthritis.​ Click on the link and take a look! Exciting news will be announced!

4P-Pharma joins forces with Qingdao Marine Biomedical Research Institute for translation research in China and Europe

4P-Pharma and Qingdao Marine Biomedical Research Institute (QMBRI) have decided to combine their expertise to jointly develop their first-in-class drug candidates in China and Europe through the signature of a Memorandum of Understanding (MoU) to deal with their respective molecules.   “[…] It is our ambition to create a fruitful and long-term partnership for our […]

4Moving Biotech at EULAR 2021

Pr. Francis Berenbaum, 4Moving Biotech’s CEO and CMO, Head of Rheumatology department at Saint-Antoine Hospital (AP-HP), will present a poster entitled « Liraglutide Has Potent Anti-inflammatory And Anti-catabolic Activity In Two Cell Types Implicated In Osteoarthritis » (# POS0373) on our recent results on 4P004 during the European congress of rheumatology (EULAR) 2021 virtual congress that will take place on June 2-5, 2021. For further […]

4P-Pharma at BIO Digital 2021

4P-Pharma will attend the upcoming BIO International Convention held virtually as BIO Digital, on June 10-11 & 14-18, 2021, as part of the Business France virtual French pavilion. Contact Roselina Lam, our Business Development and Licensing Manager, via the partnering platform or by e-mail, to learn more about us and discuss future partnerships. She is looking forward […]

The OA-BIO European Consortium, led by 4Moving Biotech, awarded a Eurostars grant to develop 4P004 through a biomarkers-driven approach

4Moving Biotech (France), Utrecht University (The Netherlands), Chondrometrics GmbH (Germany) and AO Research Institute Davos (Switzerland) have received a EUREKA-Eurostars grant award to finance its €4,2M project (OA-BIO) to complete early clinical development (Phase I) of 4P004, a first-in-class disease modifying osteoarthritis drug (DMOAD), and to identify and validate OA imaging and liquid biopsy biomarkers. […]

4Moving Biotech announces a closing of €2M investment to implement 4P004 phase 1 clinical trial on Osteoarthritis patients

4Moving Biotech, announces that it has closed a €2M investment agreement with 4P- Pharma, SATT Lutech, French Tech Seed and business angels. 4Moving Biotech is the spin-off of 4P-Pharma focusing on the development of 4P004, a first-in-class Disease Modifying OsteoArthritis Drug (DMOAD). 4Moving Biotech intends to use the proceeds to initiate a phase I clinical trial on people […]